» Articles » PMID: 9435902

Novel N-substituted 3 Alpha-[bis(4'-fluorophenyl)methoxy]tropane Analogues: Selective Ligands for the Dopamine Transporter

Overview
Journal J Med Chem
Specialty Chemistry
Date 1998 Jan 22
PMID 9435902
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

A series of N-substituted 3 alpha-[bis(4'-fluorophenyl)methoxy]tropane analogues has been prepared that function as dopamine uptake inhibitors. The N-methylated analogue of this series had a significantly higher affinity for the dopamine transporter than the parent compound, N-methyl-3 alpha- (diphenylmethoxy)tropane (benztropine, Cogentin). Yet like the parent compound, it retained high affinity for muscarinic receptors. A series of N-substituted compounds were prepared from nor-3 alpha-[bis(4'-fluorophenyl)methoxy]tropane via acylation followed by hydride reduction of the amide or by direct alkylation. All compounds containing a basic tropane nitrogen displaced [3H]WIN 35,428 at the dopamine transporter (Ki range = 8.5-634 nM) and blocked dopamine uptake (IC50 range = 10-371 nM) in rat caudate putamen, whereas ligands with a nonbasic nitrogen were virtually inactive. None of the compounds demonstrated high binding affinity at norepinephrine or serotonin transporters. Importantly, a separation of binding affinities for the dopamine transporter versus muscarinic m1 receptors was achieved by substitution of the N-methyl group with other N-alkyl or arylalkyl substituents (eg. n-butyl, allyl, benzyl, 3-phenylpropyl, etc.). Additionally, the most potent and selective analogue in this series at the dopamine transporter, N-(4"-phenyl-n-butyl)-3 alpha-[bis(4'-fluorophenyl)methoxy]tropane analogue failed to substitute for cocaine in rats trained to discriminate cocaine from saline. Potentially, new leads toward the development of a pharmacotherapeutic for cocaine abuse and other disorders affecting the dopamine transporter may be discovered.

Citing Articles

Accessing three-dimensional molecular diversity through benzylic C-H cross-coupling.

Chen S, He C, Kong M, Wang J, Lin S, Krska S Nat Synth. 2024; 2(10):998-1008.

PMID: 38463240 PMC: 10923599. DOI: 10.1038/s44160-023-00332-4.


Pharmacological Characterization of Purified Full-Length Dopamine Transporter from .

Pugh C, DeVree B, Schmidt S, Loland C Cells. 2022; 11(23).

PMID: 36497070 PMC: 9740255. DOI: 10.3390/cells11233811.


New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders.

Newman A, Ku T, Jordan C, Bonifazi A, Xi Z Annu Rev Pharmacol Toxicol. 2021; 61:609-628.

PMID: 33411583 PMC: 9341034. DOI: 10.1146/annurev-pharmtox-030220-124205.


Structure-Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability.

Slack R, Ku T, Cao J, Giancola J, Bonifazi A, Loland C J Med Chem. 2019; 63(5):2343-2357.

PMID: 31661268 PMC: 9617638. DOI: 10.1021/acs.jmedchem.9b01188.


A Novel Bromine-Containing Paroxetine Analogue Provides Mechanistic Clues for Binding Ambiguity at the Central Primary Binding Site of the Serotonin Transporter.

Slack R, Abramyan A, Tang H, Meena S, Davis B, Bonifazi A ACS Chem Neurosci. 2019; 10(9):3946-3952.

PMID: 31424193 PMC: 8272913. DOI: 10.1021/acschemneuro.9b00375.